Partner & Head of Research at Catalio Capital Management
View Live Interactive Profile →Diamantis Xylas is Partner and Head of Research at Catalio Capital Management, LP, where the firm states he manages Catalio's research team and makes investments in private breakthrough biomedical technology companies, and that he serves on the Investment Committee of Catalio's Nexus strategy and the firmwide Management Committee. He holds an MBBS from Imperial College School of Medicine, London and a BSc in Healthcare Management from Imperial College Business School, and completed two years of general surgery residency at Johns Hopkins Hospital, two years of postgraduate medical and surgical training in London, and a visiting research fellowship at Weill Cornell Medical Center. His directorships at Superluminal Medicines, Spiral Therapeutics and Medical Informatics Corp. are each confirmed by those issuers' own Form D filings. His firm biography also lists Avalyn Pharma, Monimoi Tx and Winnow Therapeutics; the Avalyn claim is not corroborated by any Avalyn Pharma SEC filing and those three are therefore not recorded as board seats.